Bosutinib [34] is a second-generation dual Abl/Src inhibitor that exhibits potent growth inhibition of CML cells in vitro, is active against multiple Imatinib-resistant BCR-Abl mutations, and has demonstrated efficacy in ongoing clinical trials for Imatinib-resistant chronic myeloid leukemia (CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.